Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Norfolk Southern Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Norfolk Southern Corporation trades at $335.84 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NSC | |
|---|---|---|
Market Cap | $29.60B | $75.15B |
Sector | Health | Technology |
52-Week High | $491.22 | $350.66 |
52-Week Low | $205.48 | $272.35 |
Enterprise Value | $27.56B | $90.70B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.
The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
